Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma

Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma

<p> <b>D.A. Dorofeev<sup>1</sup>, V.P. Balukhtina<sup>2</sup>, M.V.&nbsp;Es’kova<sup>1</sup>, K.A. Efimova<sup>1</sup>, E.V. Kirilik<sup>1</sup>, K.O.&nbsp;Luk’yanova<sup>1</sup></b> </p> <p&g...

Full description

Saved in:
Bibliographic Details
Main Authors: D.A. Dorofeev, V.P. Balukhtina, M.V. Es’kova, K.A. Efimova, E.V. Kirilik, K.O. Luk’yanova
Format: Article
Language:Russian
Published: Prime-Media 2021-09-01
Series:РМЖ "Клиническая офтальмология"
Online Access:http://clinopht.com/upload/iblock/0d3/0d300560f5211b902da9abb2243d0ec9.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841526837731131392
author D.A. Dorofeev
V.P. Balukhtina
M.V. Es’kova
K.A. Efimova
E.V. Kirilik
K.O. Luk’yanova
author_facet D.A. Dorofeev
V.P. Balukhtina
M.V. Es’kova
K.A. Efimova
E.V. Kirilik
K.O. Luk’yanova
author_sort D.A. Dorofeev
collection DOAJ
description <p> <b>D.A. Dorofeev<sup>1</sup>, V.P. Balukhtina<sup>2</sup>, M.V.&nbsp;Es’kova<sup>1</sup>, K.A. Efimova<sup>1</sup>, E.V. Kirilik<sup>1</sup>, K.O.&nbsp;Luk’yanova<sup>1</sup></b> </p> <p> <b><sup>1</sup>City Clinical Hospital No. 2, Polyclinic № 1, Chelyabinsk, Russian Federation</b> </p> <p> <b><sup>2</sup>South Ural State Medical University, Chelyabinsk, Russian Federation</b> </p> <p> <i><b>Aim</b>: to evaluate additive IOP-lowering effect of brimonidine 0.2% to achieve target IOP via enhancing maximum tolerated medical therapy for primary open-angle glaucoma (POAG).</i> </p> <p> <i><b>Patients and Methods: </b>63 patients (63 eyes) with advanced POAG and poorly controlled IOP who received prostaglandin analogs and a fixed-dose carbonic anhydrase inhibitor/beta-blocker combination were enrolled. All patients were additionally prescribed with brimonidine 0.2%. After a month, patients were divided into two groups based on achieved IOP level. In group 1, target IOP was achieved, and these patients were followed up. In group 2, target IOP was not achieved, and these patients underwent trabeculectomy. IOP was measured by elastotonometry and using the iCare tonometer.</i> </p> <p> <i><b>Results</b>: a month after prescribing α2 agonist, true IOP level reduced to 14.0 (9.5; 17.0) mm Hg in group 1 and to 17.0 (13.0; 20.0) mm Hg in group 2. At the final visit, IOP levels were within target ranges in both groups, i.e., 13.0 (11.0; 18.5) mm Hg and 13.5 (9.7; 17.2) mm Hg, respectively. Meanwhile, changes in IOP measured by various methods were significantly different. IOP reduced by 5.4% (-7.1%; 17.6%) in group 1 and by 20.7% (4.4%; 30.7%) in group 2 (p&lt;0.05) as measured by elastotonometry and by 8.3% (-11.8%; 28.6%) in group 1 and by 33.3% (13.9%; 50.7%) in group 2 as measured by iCare tonometer.</i> </p> <p> <i><b>Conclusions</b>: brimonidine 0.2% provides additional IOP reduction to enhance maximum tolerated medical therapy for advanced POAG. An estimated effect of brimonidine is a 8% reduction of IOP from the baseline. If target IOP is not achieved, a patient should be scheduled for surgery. IOP should be measured using the iCare tonometer since this device is more sensitive to minor IOP fluctuations.</i> </p> <p> <i><b>Keywords</b>: brimonidine 0.2%, maximum tolerated medical therapy for glaucoma, tonometry, elastotonometry, glaucoma, trabeculectomy, additive effect, target IOP.</i> </p> <p> <i><b>For citation: </b>Dorofeev D.A., Balukhtina V.P., Es’kova M.V. et al. Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma. Russian Journal of Clinical Ophthalmology. 2021;21(3):129–134 (in Russ.). DOI: 10.32364/2311-7729-2021-21-3-129-134.</i> </p>
format Article
id doaj-art-e0677b5ed9e44bd0a68e3d68baac0212
institution Kabale University
issn 2311-7729
2619-1571
language Russian
publishDate 2021-09-01
publisher Prime-Media
record_format Article
series РМЖ "Клиническая офтальмология"
spelling doaj-art-e0677b5ed9e44bd0a68e3d68baac02122025-01-16T09:39:38ZrusPrime-MediaРМЖ "Клиническая офтальмология"2311-77292619-15712021-09-0121331320Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucomaD.A. Dorofeev0V.P. Balukhtina1M.V. Es’kova2K.A. Efimova3E.V. Kirilik4K.O. Luk’yanova5Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399<p> <b>D.A. Dorofeev<sup>1</sup>, V.P. Balukhtina<sup>2</sup>, M.V.&nbsp;Es’kova<sup>1</sup>, K.A. Efimova<sup>1</sup>, E.V. Kirilik<sup>1</sup>, K.O.&nbsp;Luk’yanova<sup>1</sup></b> </p> <p> <b><sup>1</sup>City Clinical Hospital No. 2, Polyclinic № 1, Chelyabinsk, Russian Federation</b> </p> <p> <b><sup>2</sup>South Ural State Medical University, Chelyabinsk, Russian Federation</b> </p> <p> <i><b>Aim</b>: to evaluate additive IOP-lowering effect of brimonidine 0.2% to achieve target IOP via enhancing maximum tolerated medical therapy for primary open-angle glaucoma (POAG).</i> </p> <p> <i><b>Patients and Methods: </b>63 patients (63 eyes) with advanced POAG and poorly controlled IOP who received prostaglandin analogs and a fixed-dose carbonic anhydrase inhibitor/beta-blocker combination were enrolled. All patients were additionally prescribed with brimonidine 0.2%. After a month, patients were divided into two groups based on achieved IOP level. In group 1, target IOP was achieved, and these patients were followed up. In group 2, target IOP was not achieved, and these patients underwent trabeculectomy. IOP was measured by elastotonometry and using the iCare tonometer.</i> </p> <p> <i><b>Results</b>: a month after prescribing α2 agonist, true IOP level reduced to 14.0 (9.5; 17.0) mm Hg in group 1 and to 17.0 (13.0; 20.0) mm Hg in group 2. At the final visit, IOP levels were within target ranges in both groups, i.e., 13.0 (11.0; 18.5) mm Hg and 13.5 (9.7; 17.2) mm Hg, respectively. Meanwhile, changes in IOP measured by various methods were significantly different. IOP reduced by 5.4% (-7.1%; 17.6%) in group 1 and by 20.7% (4.4%; 30.7%) in group 2 (p&lt;0.05) as measured by elastotonometry and by 8.3% (-11.8%; 28.6%) in group 1 and by 33.3% (13.9%; 50.7%) in group 2 as measured by iCare tonometer.</i> </p> <p> <i><b>Conclusions</b>: brimonidine 0.2% provides additional IOP reduction to enhance maximum tolerated medical therapy for advanced POAG. An estimated effect of brimonidine is a 8% reduction of IOP from the baseline. If target IOP is not achieved, a patient should be scheduled for surgery. IOP should be measured using the iCare tonometer since this device is more sensitive to minor IOP fluctuations.</i> </p> <p> <i><b>Keywords</b>: brimonidine 0.2%, maximum tolerated medical therapy for glaucoma, tonometry, elastotonometry, glaucoma, trabeculectomy, additive effect, target IOP.</i> </p> <p> <i><b>For citation: </b>Dorofeev D.A., Balukhtina V.P., Es’kova M.V. et al. Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma. Russian Journal of Clinical Ophthalmology. 2021;21(3):129–134 (in Russ.). DOI: 10.32364/2311-7729-2021-21-3-129-134.</i> </p>http://clinopht.com/upload/iblock/0d3/0d300560f5211b902da9abb2243d0ec9.pdf
spellingShingle D.A. Dorofeev
V.P. Balukhtina
M.V. Es’kova
K.A. Efimova
E.V. Kirilik
K.O. Luk’yanova
Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma
РМЖ "Клиническая офтальмология"
title Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma
title_full Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma
title_fullStr Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma
title_full_unstemmed Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma
title_short Additive effect of brimonidine in maximum tolerated medical therapy for primary open-angle glaucoma
title_sort additive effect of brimonidine in maximum tolerated medical therapy for primary open angle glaucoma
url http://clinopht.com/upload/iblock/0d3/0d300560f5211b902da9abb2243d0ec9.pdf
work_keys_str_mv AT dadorofeev additiveeffectofbrimonidineinmaximumtoleratedmedicaltherapyforprimaryopenangleglaucoma
AT vpbalukhtina additiveeffectofbrimonidineinmaximumtoleratedmedicaltherapyforprimaryopenangleglaucoma
AT mveskova additiveeffectofbrimonidineinmaximumtoleratedmedicaltherapyforprimaryopenangleglaucoma
AT kaefimova additiveeffectofbrimonidineinmaximumtoleratedmedicaltherapyforprimaryopenangleglaucoma
AT evkirilik additiveeffectofbrimonidineinmaximumtoleratedmedicaltherapyforprimaryopenangleglaucoma
AT kolukyanova additiveeffectofbrimonidineinmaximumtoleratedmedicaltherapyforprimaryopenangleglaucoma

Similar Items